Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
Fiche publication
Date publication
janvier 2016
Journal
Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BALDAUF Jean-Jacques, Pr KURTZ Jean-Emmanuel, Pr MARCHAL Frédéric, Pr MATHELIN Carole, Pr PETIT Thierry
Tous les auteurs :
Akladios C, Baldauf JJ, Marchal F, Hummel M, Rebstock LE, Kurtz JE, Petit T, Afors K, Mathelin C, Lecointre L, Schrot-Sanyan S
Lien Pubmed
Résumé
To evaluate the overall survival (OS) of patients with initially inoperable advanced ovarian cancer, tubal carcinoma, or primary peritoneal carcinoma of stages III or IV undergoing neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery, according to the number of cycles performed.
Mots clés
Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Carboplatin, administration & dosage, Carcinoma, secondary, Chemotherapy, Adjuvant, adverse effects, Cytoreduction Surgical Procedures, adverse effects, Disease-Free Survival, Fallopian Tube Neoplasms, pathology, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Ovarian Neoplasms, pathology, Peritoneal Neoplasms, pathology, Retrospective Studies, Survival Rate, Taxoids, administration & dosage
Référence
Oncology. 2016 ;91(6):331-340